Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Healthy midage male and female volunteers, age =45 and =64 years, BMI range: =18.5 and =29.9 kg/m2~* Healthy elderly male and female volunteers, age =65 and =80 years, BMI range: =18.5 and = 32 kg/m2~* Male and female volunteers with mild renal impairment (CLcrd 60-90 (mL/min)) in relatively good health, age =45 and =80 years, BMI range: =18.5 and =32 kg/m2 Moderate renal impaired (CLcrd =30 to \<60 mL/min according Cockcroft\&Gault formula in relatively good health, age =45 and =80 years, BMI range: =18.5 and =32 kg/m2~Exclusion criteria:~* Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance~* Any evidence of a clinically relevant concomitant disease (other than mild renal impairment in the respective group) A significant disease is defined as a disease which in the opinion of the investigator~* put the volunteer at risk because of participation in the study~* may influence the results of the study~* may influence the volunteer¿s ability to participate in the study~* is not in a stable condition Diabetic, hypercholesterolemia or hypertensive subjects can be entered in this trial if the disease is not significant according to these criteria~* Surgery of the gastrointestinal tract (except appendectomy)~* Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders~* History of relevant orthostatic hypotension, fainting spells or blackouts.~* Chronic or relevant acute infections~* History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- healthy subjects aged 45-64 (Type: EXPERIMENTAL): Sequential Crossover to Placebo or BI 655075
- healthy elderly subjects aged 65-80 year (Type: EXPERIMENTAL): Sequential Crossover to Placebo or BI 655075
- mild renal impairment aged 45-80 years (Type: EXPERIMENTAL): Sequential Crossover to Placebo or BI 655075
- mod renal impairment aged 45-80 years (Type: EXPERIMENTAL): Sequential Crossover to Placebo or BI 655075

Based on this trial design, predict the completion outcome and termination type (if applicable).